On December 13, 2019, Organovo Holdings, Inc., Opal Merger Sub, Inc. and Tarveda Therapeutics, Inc. entered into an Agreement and Plan of Merger and Reorganization. Upon the terms and subject to the satisfaction or waiver of the conditions set in the Merger Agreement, including approval of the transaction by Organovo's stockholders and Tarveda's stockholders, Merger Sub will merge with and into Tarveda, with Tarveda becoming a wholly-owned subsidiary of Organovo and the surviving corporation of the merger. Merger Sub will merge with and into Tarveda, with Tarveda becoming a wholly-owned subsidiary of Organovo and the surviving corporation of the merger.

At the Effective Time, the Board of Directors of Organovo is expected to consist of six members designated by Tarveda and two members designated by Organovo Board of Directors. Following the Effective Time, Andrew Fromkin is expected to serve as Organovo's Chairman of the Board, President and Chief Executive Officer and Brian Roberts is expected to serve as Organovo's Chief Financial Officer. Also at the Effective Time, Organovo will change its name to “Tarveda Therapeutics, Inc.” and change its trading symbol to “TVDA.” It is anticipated that trading for Tarveda's securities will be listed on The Nasdaq Global Market or The Nasdaq Capital Market.